Follow The Filings

BCAX Bicara Therapeutics

Bicara Therapeutics earnings company data as of 4:46 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS -0.82 — —
Rev — — —

Insider trades

Open-market buys and sales by BCAX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BCAX insider trades
  • $4.8M bought by 1 insider
  • None no sales outside a trading plan
  • $9.9M sold by 4 insiders under 10b5-1 plans
  1. Ryan Cohlhepp CEO
    Planned sale
    $401K 17,500 shares at $22.90 8.8% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  2. Ivan Hyep CFO
    Planned sale
    $350K 12,500 shares at $27.97 8.8% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  3. Claire Mazumdar CEO
    Planned sale
    $280K 10,000 shares at $27.98 2.7% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  4. Ryan Cohlhepp COO
    Planned sale
    $525K 18,750 shares at $27.98 9.4% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  5. Claire Mazumdar CEO
    Planned sale
    $284K 10,000 shares at $28.42 2.7% of stake
    Traded Jul 10 Filed Jul 14
    ↗
  6. Ryan Cohlhepp COO
    Planned sale
    $833K 28,750 shares at $28.98 14% of stake
    Traded Jul 8–9 Filed Jul 10
    ↗
  7. Ivan Hyep CFO
    Planned sale
    $808K 28,000 shares at $28.85 18% of stake
    Traded Jul 8 Filed Jul 10
    ↗
  8. Ivan Hyep CFO
    Planned sale
    $188K 9,200 shares at $20.42 6% of stake
    Traded May 21 Filed May 26
    ↗
  9. Claire Mazumdar CEO
    Planned sale
    $301K 15,000 shares at $20.04 4% of stake
    Traded May 18 Filed May 20
    ↗
  10. Ryan Cohlhepp COO
    Planned sale
    $254K 12,500 shares at $20.29 6.1% of stake
    Traded May 15 Filed May 18
    ↗
  11. David Raben Chief Medical Officer
    Planned sale
    $126K 5,500 shares at $22.88 9% of stake
    Traded Apr 27 Filed Apr 28
    ↗
  12. Ivan Hyep CFO
    Planned sale
    $212K 9,200 shares at $23.00 6% of stake
    Traded Apr 21 Filed Apr 22
    ↗
  13. Claire Mazumdar CEO
    Planned sale
    $354K 15,000 shares at $23.61 4% of stake
    Traded Apr 20 Filed Apr 20
    ↗
  14. Ryan Cohlhepp COO
    Planned sale
    $288K 12,500 shares at $23.01 6% of stake
    Traded Apr 15 Filed Apr 17
    ↗
  15. David Raben Chief Medical Officer
    Planned sale
    $104K 5,500 shares at $18.95 9% of stake
    Traded Mar 25 Filed Mar 26
    ↗

Also filed in the last 12 months, not counted as buying or selling: 47 option exercises.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.